Table 2 Difference in clinicopathological features due to TILs in younger and elderly patients
Parameters | Tumor-infiltrating lymphocytes (n = 191) | ||
|---|---|---|---|
Low (n = 96) | High (n = 95) | p value | |
Age (years) | |||
 ≤ 45 | 31 (32.3%) | 44 (46.3%) | 0.047 |
 > 60 | 65 (67.7%) | 51 (53.7%) | |
Tumor size (mm) | |||
 ≤ 20.0 | 20 (20.8%) | 14 (14.7%) | 0.271 |
 > 20.0 | 76 (79.2%) | 81 (85.3%) | |
Skin infiltration | |||
 Negative | 71 (74.0%) | 87 (91.6%) | 0.001 |
 Positive | 25 (26.0%) | 8 (8.4%) | |
Lymph node status | |||
 Negative | 33 (34.4%) | 39 (41.1%) | 0.341 |
 Positive | 63 (65.6%) | 56 (58.9%) | |
Estrogen receptor | |||
 Negative | 37 (38.5%) | 67 (70.5%) | < 0.001 |
 Positive | 59 (61.5%) | 28 (29.5%) | |
Progesterone receptor | |||
 Negative | 55 (57.3%) | 76 (80.0%) | 0.001 |
 Positive | 41 (42.7%) | 19 (20.0%) | |
Hormone receptor | |||
 Negative | 35 (36.5%) | 66 (69.5%) | < 0.001 |
 Positive | 61 (63.5%) | 29 (30.5%) | |
HER2 | |||
 Negative | 69 (71.9%) | 47 (49.5%) | 0.002 |
 Positive | 27 (28.1%) | 48 (50.5%) | |
Ki67 | |||
 ≤ 14% | 37 (38.5%) | 25 (26.3%) | 0.071 |
 > 14% | 59 (61.5%) | 70 (73.7%) | |
ORR | |||
 Non-responders | 18 (18.8%) | 4 (4.2%) | 0.002 |
 Responders | 78 (81.2%) | 91 (95.8%) | |
Pathological response | |||
 Non-pCR | 79 (82.3%) | 45 (47.4%) | < 0.001 |
 pCR | 17 (17.7%) | 50 (52.6%) | |